SEQIRUS VACCINES LIMITED

Active
Company number 03970089Private limited companyIncorporated 2000

Key figures

£254,200,000-1.2%
Net assets 2024/25
-1.2%
Average annual change 2023/24–2024/25
0100 m200 m300 m2023/242024/25

† SEQIRUS VACCINES LIMITED filed these accounts on paper, so Companies House publishes them only as a scanned image. The figures for the years marked † were read automatically from the scan and kept only where the statements add up (for example net assets equal total equity), but a reading error is still possible — check the original accounts at Companies House.

Ratios

2024/25

Sector comparison

SIC 21100

Where the company stands among the 1,055 active companies whose first SIC code is 21100 (Manufacture of basic pharmaceutical products).

Turnover£175,200,000
Higher than 87% · median £23,360,137 among 97 that publish turnover
Net assets£254,200,000
Higher than 98% · median £41,497
Total assets£254,200,000
Higher than 96% · median £308,978
Cash£4,300,000
Higher than 90% · median £135,555
Employees671
Higher than 99% · median 1
Company age26.6 years
Older than 82% · median 9.0 years
Largest in this sector by net assets
  1. GE HEALTHCARE LIMITED£5.6bn
  2. THERMO FISHER SCIENTIFIC LIFE HOLDINGS LIMITED£1.4bn
  3. LRC PRODUCTS LIMITED£1bn
  4. SMITHKLINE BEECHAM LIMITED£940m
  5. DECHRA LIMITED£780.1m
  6. IPSEN BIOPHARM LIMITED£588.2m
  7. ORTHO-CLINICAL DIAGNOSTICS£295.7m
  8. BESPAK EUROPE LIMITED£256m
  9. SEQIRUS VACCINES LIMITED£254.2m
  10. IOVANCE BIOTHERAPEUTICS UK LTD£199.7m

Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 1,055. The line on each bar marks the median.

Summary: SEQIRUS VACCINES LIMITED

What kind of company is it?

SEQIRUS VACCINES LIMITED is a private limited company registered with Companies House under company number 03970089. It was incorporated on 11 Apr 2000. Its status is active. The registered office is in Merseyside (L24). Its nature of business (SIC 2007) is manufacture of basic pharmaceutical products (21100), manufacture of pharmaceutical preparations (21200).

How is the company doing financially?

The latest accounts in the database are for 2024/25 (period ending 30 Jun 2025); the company files full accounts. Turnover was £175,200,000. Profit for the year was £9,000,000. Net assets were £254,200,000, down 1.2% on the previous year. Cash at bank and in hand was £4,300,000. Total assets were £254,200,000 and total liabilities £110,300,000. The company had an average of 671 employees. Figures are available for 2 financial years (2023/24–2024/25).

How does it compare with similar companies?

Compared with 1,055 active companies whose first SIC code is 21100: By turnover it ranks higher than 87% of the 97 that publish turnover (median £23,360,137). By net assets it ranks higher than 98% of them (median £41,497). By total assets it ranks higher than 96% of them (median £308,978). By cash it ranks higher than 90% of them (median £135,555). By number of employees it ranks higher than 99% of them (median 1). It is older than 82% of them (median age 9.0 years).

Does it supply the public sector?

The company is named as the supplier in one public contract award notice, from COMMERCIAL MEDICINES UNIT. 1 of the awards is shared with other suppliers, typically framework agreements.

What do public registers and reports show?

HMRC lists it as an importer of goods, mainly dairy, eggs and honey, pharmaceuticals, machinery. HMRC lists it as an exporter of goods, mainly pharmaceuticals, machinery, optical, medical and measuring instruments. In its latest payment practices report it took an average of 42 days to pay suppliers, and 20% of invoices were not paid within agreed terms. Its gender pay gap report for 2025/26 shows median hourly pay for women 2.3% lower than for men. It has modern slavery statements on the government registry for 6 years.

Who runs and controls the company?

One person with significant control is registered.

When are its next filings due?

The next accounts are due by 31 Mar 2027. The next confirmation statement is due by 12 Mar 2027.

Filed accounts2023/24–2024/25
2023/24 †2024/25 †
Turnover197,700,000175,200,000
Profit for the year14,000,0009,000,000
Cash at bank and in hand2,400,0004,300,000
Total assets257,400,000254,200,000
Total liabilities123,100,000110,300,000
Net assets / total equity257,400,000254,200,000
Average number of employees675671

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Public contracts

1 contract

SEQIRUS VACCINES LIMITED is named as a supplier in 1 public contract award notice from COMMERCIAL MEDICINES UNIT. 1 award is shared with other suppliers.

Contract
  1. NHS framework agreement for supply of seasonal influenza vaccine, for delivery during the 2017/18 flu season‡COMMERCIAL MEDICINES UNIT · shared by 5 suppliers

From contract award notices on Contracts Finder (since 2016) and Find a Tender (since 2021), published by the Cabinet Office under the Open Government Licence v3.0. Values are as published by the buyer and usually cover the whole contract term; the total leaves out awards shared between several suppliers, where the published figure is a ceiling for all of them, placeholder values and single figures of £1 billion or more. Notices marked ‡ do not state a company number and were linked by an exact match on the registered name. Contracts below the publication thresholds and those of devolved buyers that publish elsewhere are not included.

Statutory reporting

Payment practices1 Jan 2026 – 30 Jun 2026
Average time taken to pay invoices
42 days
Invoices not paid within agreed terms
20%
Standard payment terms
60 days
Member of a payment code
No
  • Within 30 days 49%
  • 31 to 60 days 43%
  • After 60 days 8%
Earlier periods (7)
Period ending
Days to pay
Within 30 days
Late
31 Dec 2025
47
60%
18%
30 Jun 2025
42
59%
23%
31 Dec 2024
45
53%
32%
30 Jun 2024
53
47%
39%
31 Dec 2023
45
58%
21%
30 Jun 2023
46
59%
20%
31 Dec 2022
42
57%
18%

View the latest report on GOV.UK

Gender pay gap2025/26
Median hourly pay
women 2.3% lower
Mean hourly pay
women 2.3% lower
Median bonus pay
women 35% higher
Employer size
500 to 999 employees
Lower pay quarter38% womenLower middle28% womenUpper middle37% womenUpper pay quarter25% women
Earlier years (8)
Year
Median hourly pay
Mean hourly pay
2024/25
women 2.9% lower
women 2.9% lower
2023/24
women 2.9% lower
women 3.8% lower
2022/23
women 1.6% lower
women 2.3% lower
2021/22
women 7.9% lower
women 4.3% lower
2020/21
women 3.6% lower
women 5% lower
2019/20
women 5.7% lower
women 5.2% lower
2018/19
women 6.6% lower
no gap
2017/18
women 13% lower
women 7% lower

A positive gap means women's average hourly pay is lower than men's across the whole employer; it is not a comparison of pay for the same work. View on the Gender pay gap service

Modern slavery statements6
2025
Statement · summary on GOV.UK · group statement (CSL Limited)
2024
Statement · summary on GOV.UK · group statement (CSL Limited)
2023
Statement · summary on GOV.UK · group statement (CSL Limited)
Earlier years (3)
2022
Statement · summary on GOV.UK · group statement (CSL Limited)
2021
Statement · summary on GOV.UK · group statement (CSL Limited)
2020
Statement · summary on GOV.UK · group statement (CSL Limited)

Figures the company reported itself to the government's Check payment practices service, Gender pay gap service and Modern slavery statement registry (Open Government Licence v3.0). Only large companies and employers with 250 or more staff have to report, so most companies have nothing here.

Registers and licences

International trade‡

Listed by HMRC as an importer of goods in 12 of the last 12 months on record, most recently August 2026. Main goods: dairy, eggs and honey, pharmaceuticals, machinery, optical, medical and measuring instruments and miscellaneous chemicals.

Listed by HMRC as an exporter of goods in 12 of the last 12 months on record, most recently August 2026. Main goods: pharmaceuticals, machinery, optical, medical and measuring instruments, miscellaneous chemicals and plastics.

From HMRC's monthly lists of importers and exporters. Traders can ask to be left off the lists, so absence does not mean a company does not trade.

Sources: Charity Commission for England and Wales, Care Quality Commission, Home Office and HM Revenue & Customs, under the Open Government Licence v3.0. Entries marked ‡ come from lists that do not state a company number and were linked by an exact match on the registered name.

History

7 events
  1. Seqirus Limited registered as a person with significant control
  2. Seqirus Vaccines Holdings Limited ceased to be a person with significant control
  3. Financial year 2024/25 endedAccounts: turnover £175.2m, net assets £254.2m, 671 employees
  4. Financial year 2023/24 endedAccounts: turnover £197.7m, net assets £257.4m, 675 employees
  5. Seqirus Vaccines Holdings Limited registered as a person with significant control
  6. Name changed to SEQIRUS VACCINES LIMITEDPreviously NOVARTIS VACCINES AND DIAGNOSTICS LIMITED
  7. Company incorporatedPrivate limited company

Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current and former persons with significant control, and the end of each financial year with figures in the database.